TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29405819
Drug: Rebound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebound therapy exercise (10-30 minutes, three sessions a week for 12 weeks)
Study: 23657857
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) + L-NAME
Study: 23657857
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) + L-NAME in DM
Study: 23657857
Drug: Losartan (LOS)
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan (LOS) pretreatment + L-NAME in DM
Study: 19192659
Drug: 20,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20,000 IU erythropoetin beta twice a week (group B)
Study: 16875904
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy with the ARB valsartan
Study: 31667693
Drug: Sterile carbon
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sterile carbon particle suspension (SCPS)
Study: 28425497
Drug: Memantine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine 20 mg (p.o.)
Study: 23243228
Drug: Pleasant contact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pleasant contact (PL) - chicks stroked gently for 30 s once daily from d 1 to 28
Study: 23243228
Drug: Unpleasant contact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unpleasant contact (UNPL) - chicks suspended by legs and exposed to noise for 15 s once daily from d 1 to 28
Study: 23243228
Drug: PL and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PL and PL-UNPL treatments
Study: 21991728
Drug: Ropivacaine 0.25%
Normalized name: ROPivacaine 0.25%-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.25% and morphine 0.2 mg/mL
Study: 21991728
Drug: Ropivacaine 0.25%
Normalized name: ROPivacaine 0.25%-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.25% and morphine 0.2 mg/mL and Xefocam 0.8 mg/mL
Study: 19960134
Drug: Diuretic-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic-based treatment (n=20)
Study: 19960134
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blocker (CCB)-based treatment (n=18)
Study: 16901484
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg/d) for >or=3 weeks
Study: 3042576
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg b.i.d. + placebo b.i.d.)
Study: 23447607
Drug: DA antagonist
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA antagonist administration
Study: 19825284
Drug: Dexamethasone (intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (intravenously once a day for 4 weeks, then orally once daily for another 4 weeks)
Study: 19825284
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard anti-tuberculosis drugs only)
Study: 9264417
Drug: Propranolol (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (8 mg cumulative dose or maximum heart rate reduction of 25%)
Study: 29576125
Drug: PECs blocks
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: PECs blocks (levobupivacaine 0.25%, 10 ml PECs I and 20 ml PECs II)
Study: 29576125
Drug: LA infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LA infusion (levobupivacaine 0.1% at 10 ml h‐1 for 24 h)
Study: 29576125
Drug: Both PECs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both PECs and LA infusion
Study: 28410749
Drug: K-877 (pemafibrate)
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-877 (pemafibrate) 0.1, 0.2, and 0.4 mg/day in combination with pitavastatin for 12 weeks
Study: 28410749
Drug: K-877 (pemafibrate)
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-877 (pemafibrate) 0.2 mg/day (fixed dose) and 0.2 (0.4) mg/day (conditional up-titration) in combination with any statin for 24 weeks
Study: 28410749
Drug: K-877 add-on
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-877 add-on therapy
Study: 28410749
Drug: K-877 combination
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-877 combination therapy
Study: 16942565
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with tree pollen extract, accumulated weekly dose of 200,000 SQ-U, 5 days a week for up to 18 months
Study: 16942565
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with tree pollen extract, accumulated weekly dose of 24,000 SQ-U, 5 days a week for up to 18 months
Study: 8390528
Drug: Lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 20 mg once a day
Study: 1390326
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg once a day
Study: 11889776
Drug: Droperidol 2.5
Normalized name: droperidol 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 2.5 mg
Study: 19294678
Drug: Oral azithromycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral azithromycin, 500 mg per day for 3 days before amniocentesis
Study: 1413580
Drug: Drugs only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs only
Study: 15100593
Drug: Oxcarbazepine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxcarbazepine (150 mg/day, titrated to 1200 mg/day)
Study: 15100593
Drug: Oxcarbazepine (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxcarbazepine (1200 mg/day during Maintenance Phase)
Study: 11281158
Drug: hPTH plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: hPTH plus hormone-replacement therapy (HRT)
Study: 9397118
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy (ERT) with 2 mg/day of oral micronized estradiol for 12 weeks
Study: 25540980
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HP and LGI diets
Study: 18626487
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine jelly
Study: 12648114
Drug: Patient-maintained sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-maintained sedation using a target-controlled infusion of propofol
Study: 1425899
Drug: alfentanil 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfentanil 15 micrograms.kg‐1, vecuronium 0.01 mg.kg‐1, thiopentone 3‐4 mg.kg‐1, suxamethonium 1 mg.kg‐1
Study: 1425899
Drug: vecuronium 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: vecuronium 0.01 mg.kg‐1, thiopentone 3‐4 mg.kg‐1, suxamethonium 1 mg.kg‐1
Study: 4064558
Drug: Naloxone (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (intravenous administration)
Study: 20711087
Drug: Passive removal
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive removal of silicone oil with 23-G transconjunctival sutureless system
Study: 20711087
Drug: 20-G active
Normalized name: ubiquinol 20 MG/ML [Active Q]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-G active silicone oil removal using all three 20-G ports
Study: 18652603
Drug: Adalimumab therapy
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab therapy (160 mg loading dose at week 0, 80 mg at week 2, 40 mg every other week starting at week 4)
Study: 31867564
Drug: Adalimumab therapy
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab therapy
Study: 15740542
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii (250 mg, orally, twice daily during antibiotic treatment)
Study: 8777661
Drug: Commercial sweet-tasting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial sweet-tasting solution
Study: 8777661
Drug: 25% sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% sucrose solution
Study: 11937721
Drug: 50% sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% sucrose solution
Study: 1610998
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's (LR) solution (group I)
Study: 1610998
Drug: LR with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: LR with 5% dextrose solution (group II)
Study: 6706438
Drug: pirbuterol 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: pirbuterol 20 mg
Study: 26197031
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg · d(‐1) for 6 months
Study: 20233153
Drug: Weight maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight maintenance interventions following family-based behavioral weight loss treatment for HIGH children (n = 71)
Study: 20233153
Drug: Weight maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight maintenance interventions following family-based behavioral weight loss treatment for LOW children (n = 130)
Study: 29206136
Drug: Diascorea extracts
Normalized name: Dioscorea communis top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diascorea extracts (12 mg/dose, 2 sachets daily)
Study: 25710190
Drug: Red Bull
Normalized name: acid red 35
DrugBank: Pantothenic acid (DB01783)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red Bull (9.4 mL/kg body mass containing 3 mg/kg body mass caffeine)
Study: 25710190
Drug: Anhydrous caffeine
Normalized name: Anhydrous caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anhydrous caffeine (3 mg/kg body mass in capsule form)
Study: 22137516
Drug: BIS‐guided target‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS‐guided target‐controlled infusion of propofol
Study: 24817819
Drug: Ropivacaine 0.75%
Normalized name: ROPivacaine 0.75% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.75% plus perineural dexamethasone 4 mg (group Dperi)
Study: 24817819
Drug: Ropivacaine 0.75%
Normalized name: ROPivacaine 0.75% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.75% plus intravenous dexamethasone 4 mg (group Div)
Study: 16787138
Drug: PDE3 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PDE3 inhibitors
Study: 16787138
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with beta-adrenergic receptor antagonists
Study: 12841882
Drug: Vaginal ring
Normalized name: NuvaRing Vaginal Ring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal ring releasing estradiol acetate (50 microg/day) plus placebo tablets
Study: 12841882
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol (1 mg/day) plus placebo vaginal ring
Study: 8325043
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate via 'Autohaler' inhalation device
Study: 8325043
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate via conventional metered dose inhaler
Study: 3822496
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine infusion (5 mg/kg body weight)
Study: 28611089
Drug: Free and
Normalized name: Free and Clear
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free and convenient access to a carefully selected list of 125 essential medicines (based on the WHO's Model List of Essential Medicines)
Study: 28611089
Drug: Usual means
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual means of medicine access
Study: 16543745
Drug: Substance misuse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance misuse with psychiatric concurrent disorders
Study: 14507560
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of 0.5% hyperbaric bupivacaine
Study: 14507560
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of 0.5% hyperbaric bupivacaine
Study: 14507560
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of 0.5% hyperbaric bupivacaine
Study: 6844470
Drug: Weekly sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly sessions with one therapist
Study: 6844470
Drug: Monthly sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly sessions with one therapist
Study: 30221566
Drug: PRG-loaded NVTEs
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PRG-loaded NVTEs vaginal gel
Study: 30286920
Drug: Less than
Normalized name: IgA less than or equal to 50 mcg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less than weekly hypoglycemia
Study: 30286920
Drug: Greater than
Normalized name: immune globulin,alpha (IgA) greater than 50 mcg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Greater than or equal to weekly hypoglycemia
Study: 26355167
Drug: 8.5 mm-long
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8.5 mm-long implants
Study: 25124505
Drug: Group anger
Normalized name: After banger
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Group anger management treatment (AMT)
Study: 22011557
Drug: Ivabradine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine 15 mg
Study: 22011557
Drug: Ivabradine in
Normalized name: Product containing ivabradine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine in long-term β-blocker therapy
Study: 22011557
Drug: Metoprolol in
Normalized name: metoprolol Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol in long-term β-blocker therapy
Study: 17465661
Drug: Adper Prompt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adper Prompt L‐Pop after one light cure
Study: 17465661
Drug: Adper Prompt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adper Prompt L‐Pop after two light cures
Study: 17465661
Drug: SEP Adper
Normalized name: Asper-Flex
DrugBank: Trolamine salicylate (DB11079)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SEP Adper Prompt L‐Pop
Study: 15074085
Drug: Angelica Injection
Normalized name: Angelica
DrugBank: Angelica archangelica root (DB14283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angelica Injection (AI)
Study: 15074085
Drug: Compound salvia
Normalized name: Salvia sclarea seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound salvia
Study: 15074085
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular dextran injection
Study: 2125546
Drug: Monophasic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monophasic preparation (150 micrograms LNG and 30 micrograms EE)
Study: 2125546
Drug: Triphasic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic preparation (low doses of LNG and EE in various proportions)
Study: 6793373
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin 0.5 mg
Study: 6793373
Drug: Oral nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nitroglycerin 6.5 mg
Study: 15725050
Drug: Hydrofluoroalkane metered
Normalized name: HYDROFLUOROALKANE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrofluoroalkane metered dose inhaler (HFA-MDI)
Study: 12011296
Drug: Pramipexole (PPX)
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pramipexole (PPX) at doses of 1.5 mg/d and 4.5 mg/d
Study: 10216808
Drug: Eprosartan +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan + Hydrochlorothiazide (HCTZ) (12.5‐25 mg o.d. added if SitDBP > or = 90 mmHg)
Study: 2129650
Drug: ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ranitidine 150 mg b.d.
Study: 799984
Drug: Nefopam 30
Normalized name: nefopam 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam 30 mg
Study: 799984
Drug: Nefopam 60
Normalized name: nefopam 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam 60 mg
Study: 23341426
Drug: Water-ethanol (95%)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Water-ethanol (95%) solution (control)
Study: 19089448
Drug: Family-based group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based group treatment
Study: 9562311
Drug: Aspirin 990
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 990 mg/day + Dipyridamole 225 mg/day
Study: 28258090
Drug: Metformin (850mg)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (850mg)
Study: 28258090
Drug: Placebo (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (for Metformin)
Study: 23944945
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of FPND and FESS
Study: 21333458
Drug: COMBOHP (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: COMBOHP (combination high protein diet; 0.92% creatine monohydrate and 2.75% dextrose with minimum 16% crude protein)
Study: 21333458
Drug: COMBO (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: COMBO (combination diet; 0.92% creatine monohydrate and 2.75% dextrose)
Study: 11641592
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of amphetamine combined with physiotherapy for 10 sessions over 5 weeks
Study: 22801937
Drug: Vaginal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal estrogen therapy (estradiol, E(2)) with vaginal mesh prolapse surgery (VM)
Study: 22801937
Drug: Vaginal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal estrogen therapy (estradiol, E(2)) with minimally invasive sacral colpopexy (MISC)
Study: 22801937
Drug: Vaginal mesh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal mesh prolapse surgery (VM) without vaginal estrogen therapy
Study: 22801937
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive sacral colpopexy (MISC) without vaginal estrogen therapy
Study: 21365652
Drug: medication
Normalized name: Acne Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: medication
Study: 8606694
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate (600 mg b.i.d. x 6 days)
Study: 1413136
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (6 g daily for four weeks)
Study: 31204333
Drug: Capsule lycopene
Normalized name: lycopene Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule lycopene
Study: 31204333
Drug: Capsule lycopene
Normalized name: lycopene Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule lycopene and injection dexamethasone
Study: 31204333
Drug: Injection dexamethasone
Normalized name: dexamethasone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection dexamethasone and hyaluronidase
Study: 24483757
Drug: nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine 20 mg Q 8‐hourly
Study: 24483757
Drug: progesterone 400
Normalized name: progesterone 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: progesterone 400 mg daily
Study: 22019244
Drug: Multiple kilovoltage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple kilovoltage (kV) and megavoltage (MV) imaging of implanted gold markers during treatment
Study: 16098253
Drug: LDCI 5‐FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDCI 5‐FU 300 mg/m(2) per day for 28 days every 5 weeks
Study: 16098253
Drug: HDI 5‐FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDI 5‐FU 2,600 mg/m(2) for 24 hours each week
Study: 7742151
Drug: Simvastatin (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (10-40 mg day-1 for three periods of 6 weeks)
Study: 7742151
Drug: Pravastatin (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (10-40 mg day-1 for three periods of 6 weeks)
Study: 2036922
Drug: Metoclopramide administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide administered intravenously every 8 hours until solid food diet tolerated
Study: 7091898
Drug: Combined maneuvers
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined maneuvers (postural drainage, deep breathing with vibrations, and percussion) administered by a physiotherapist
Study: 29017481
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral group therapy (STEpS)
Study: 25910804
Drug: SR-nitrite (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR-nitrite (80 mg, twice daily by mouth for 21 days)
Study: 17970675
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal therapy during gestation
Study: 15496697
Drug: Midazolam 2-4
Normalized name: midazolam 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 2-4 mg
Study: 15496697
Drug: Etomidate 0.2-0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate 0.2-0.3 mg/kg
Study: 11563998
Drug: Pantoprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (20 mg)
Study: 8065835
Drug: High-dose surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose surfactant (200 mg/kg, max 600 mg/kg)